Hansa Biopharma Ab · OMXSTO:HNSA

Hansa Biopharma Ab — Merger or Acquisition (May 2026)

15 slides from Hansa Biopharma Ab's merger presentation, May 19, 2026

  1. Slide 1: Hansa's €115 Million Out Licensing of Idefirix in Europe and MENA to SERB

    ® Hansa’s €115 Million Out Licensing of Idefirix in Europe and MENA to SERB May 19, 2026

  2. Slide 2: Forward-looking statements

    ® Forward-looking statements This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will o

  3. Slide 3: Conference Call: Agenda

    Conference Call: Agenda ® May 19, 2026 Transaction Overview Renée Aguiar-Lucander CEO Financial Update Evan Ballantyne CFO Close and Q&A Renée Aguiar-Lucander CEO © 2026, Hansa Biopharma AB 3

  4. Slide 4: Transaction Background

    Transaction Background ® ® SITUATION PROCESS OUTCOME European backdrop Strategic fit & resources Out-licensing agreement • Significant market opportunity • Significant inbound interest • Transformative €115 million deal from multiple potential partners validating franchise and market • Fragmented ma

  5. Slide 5: Transaction Overview

    Transaction Overview ® Transaction Scope Partnership Responsibilities SERB Hansa Exclusive out-licensing of Idefirix for transplantation in EU, UK, Switzerland, Norway, Liechtenstein, Iceland and MENA to SERB • Commercialization & • PAES readout medical affairs across licensed territories from closi

  6. Slide 6: SERB at a Glance

    SERB at a Glance ® • Global specialty pharmaceutical company with 25+ years of experience in rare diseases, rare medical emergencies and medical countermeasures • Diversified portfolio in Critical Care and Rare Disease with >70 products • Direct presence in 18 countries. Distribution footprint throu

  7. Slide 7: Transaction Timeline

    Transaction Timeline ® ® Illustrative Transaction Timeline Post Announcement and Post Closing and Going Forward Before Closing  Signing • Responsibility for European  FDI review (expected 30-60 days) • Business as usual commercialization related activities transferred to SERB  Start of employee c

  8. Slide 8: Hansa Focus Going Forward

    Hansa Focus Going Forward ® ® Robust Preparations Clinical Development of Other Key Activities for US Launch HNSA-5487 in GBS  Leadership team complete • Interactions with FDA • FDA BLA review process regarding clinical development  Field presence strengthened program • Continue to drive early pip

  9. Slide 9: Key Takeaways

    Key Takeaways ® • €110 million upfront consideration for out licensing of Idefirix in Europe, UK, Switzerland, Norway, Liechtenstein, Iceland and MENA. Additional €5 million payment upon EMA acceptance of submission for conversion from conditional to full approval • Substantial non-dilutive financin

  10. Slide 10: Conference Call: Agenda

    Conference Call: Agenda ® May 19, 2026 Transaction Overview Renée Aguiar-Lucander CEO Financial Update Evan Ballantyne CFO Close and Q&A Renée Aguiar-Lucander CEO © 2026, Hansa Biopharma AB 10

  11. Slide 11: Estimated Financial Impact of Transaction

    Estimated Financial Impact of Transaction ® Cash Position o Transaction (upfront €110M or 1.3 BSEK) significantly increases Hansa’s cash position o Pro forma cash based on Q1 2026 cash on hand 1.9 BSEK Pro Forma Q1 2026 Cash with Out Licensing Agreement* o Upon EMA acceptance of filing for approval;

  12. Slide 12: Conference Call: Agenda

    Conference Call: Agenda ® May 19, 2026 Transaction Overview Renée Aguiar-Lucander CEO Financial Update Evan Ballantyne Chief Financial Officer Close and Q&A Renée Aguiar-Lucander CEO © 2026, Hansa Biopharma AB 12

  13. Slide 13: Hansa Today

    Hansa Today ® • One year in – structural changes across the business implemented. Substantial improvements achieved with regards to financial stability, runway, pipeline strategy, internal expertise and experience. • Positive outlook for the year reflecting several key data related milestones and po

  14. Slide 14: Hansa Biopharma Capital Markets Day

    Hansa Biopharma Capital Markets Day ® Featuring Key European and US KOLs Thursday 25th of June, 2026 from 9:00 AM to 12:00 PM EDT • In-Person: The St. Regis Hotel New York, U.S. Location: • Virtual: Live webcast In-Person Sign-up and Webcast Access: More details and full agenda to follow Hansa Bioph

  15. Slide 15: Q&A

    ® Q&A © 2026, Hansa Biopharma AB 15

Hansa Biopharma — Merger or Acquisition (May 2026) on 6ix